CAS NO: | 95809-78-2 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
Molecular Weight (MW) | 388.59 |
---|---|
Formula | C22H28O2S2 |
CAS No. | 95809-78-2 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 78 mg/mL (200.7 mM) |
Water: <1 mg/mL | |
Ethanol: 78 mg/mL (200.7 mM) | |
Solubility (In vivo) | 1% DMSO+30% polyethylene glycol+1% Tween 80: 30 mg/mL |
Synonyms | CPI613; CPI-613; Devimistat; CPI 613 Chemical Name: 6,8-bis(benzylthio)octanoic acid SMILES Code: O=C(O)CCCCC(SCC1=CC=CC=C1)CCSCC2=CC=CC=C2 |
In Vitro | In vitro activity:In vitro, CPI-613 produces the selective toxicity against several tumor cell lines including H460 human lung cancer cells and Saos-2 human sarcoma cells with EC50 of 120 μM and 120 μM, respectively. CPI-613 disrupts H460 cancer cell mitochondrial metabolism including inhibition of PDH complex activity and loss of mitochondrial membrane potential in a time- and drug dose-dependent fashion. In addition, CPI-613 (240 μM) also induces both apoptotic and non-apoptotic cell death in H460 human lung cancer and Saos-2 human sarcoma cells. Cell Assay: Devimistat (CPI-613) is a lipoic acid analog that inhibits pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, disrupts mitochondrial metabolism and shows strong antitumor activity. |
---|---|
In Vivo | CPI-613 (25 mg/kg) has potent anticancer activity in a human tumor xenograft model of of a pancreatic tumor cell (BxPC-3). Similarly, CPI-613 (10 mg/kg) also produces significant tumor growth inhibition of H460 human non-small cell lung carcinoma in mouse model. Besides, CPI-613 produces little or no side-effect toxicity in expected therapeutic dose ranges in large animal models and has the maximum tolerated dose of 100 mg/kg in mice. |
Animal model | CD1 nu/nu mice bearing BxPC-3 and H460 cells tumor models |
Formulation & Dosage | Dissolved in DMSO and then diluted in water.; 25 mg/kg; i.p. administration |
References | J Mol Med (Berl). 2011 Nov;89(11):1137-48. |